Endometrial stromal sarcoma, Endometriosis, Dyspareunia, Dysmenorrhea, Case reports
Received: Jul 17, 2023 Revised: Dec 4, 2023 Accepted: Dec 5, 2023
Correspondence to: Aarthi S Jayraj
Department of Gynecologic Oncology, James Cook University Hospital,
South Tees NHS Foundation Trust, Middlesbrough, UK
Tel: +44-1642-54858
E-mail:
[email protected]
Copyright © 2023 Korean Society of Surgical Oncology
This is an Open Access article distributed under the terms of the Creative Commons Attri-
bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which
permits unrestricted non-commercial use, distribution, and reproduction in any medium,
provided the original work is properly cited.
74 Korean Journal of Clinical Oncology
formed. Computed tomography pelvis showed normal uterus and
adnexa with nodularity and thickening of posterior vaginal fornix
with ill-defined planes posteriorly with rectum (Fig. 1B). Biopsy of
the irregular nodular areas in posterior fornix showed proliferative
endometrial glands and cellular stroma suggestive of extrauterine
endometriosis (Fig. 1C).
The patient opted for medical therapy and was started on le -
uprolide acetate 3.75 mg intramuscular injection monthly for 3
months. There was a significant improvement in her symptoms
with disappearance of the vaginal forniceal lesions. Thereafter, the
patient was started on depot intramuscular injection of medroxy-
progesterone acetate 150 mg every 3 monthly for 12 months. Eigh-
teen months after diagnosis, she presented again with blood-mixed
vaginal discharge for 3 months with dyspareunia and dyschezia.
On per speculum examination, there was an irregular exophytic
necrotic growth in posterior vaginal fornix. The cervix appeared
A B C
Fig. 1. (A) Image showing raised irregular areas in posterior fornix on speculum examination. (B) Computed tomography pelvis axial image
showing ill-defined planes of posterior wall of vagina with the rectosigmoid. (C) Biopsy from posterior fornix shows presence of endometrial
glands and stroma suggestive of endometriosis (hematoxylin and eosin stain, ×100).
Fig. 2. (A) T2 weighted magnetic resonance imaging image of pelvis showing heterogeneously enhancing mass of 7×6 cm at posterior vagi-
nal wall with exophytic component and necrosis with diffusion restriction and loss of fat planes with the rectosigmoid colon. (B) En bloc
specimen of excised tumor along with uterus, ovaries, rectum, vagina and rectosigmoid colon up to perineum.
A B
Seema Singhal et al. • ESS from vaginal endometriosis
www.kjco.org 75
tubes and ovary were normal with no evidence of endometriosis.
The tumor cells were immunopositive for CD10, ER, PR and focal-
ly for cyclin D1 and desmin, while negative for SMA, consistent
with a diagnosis of ESS (Fig. 3). There were foci of endometriosis
found embedded within the periphery of the tumor. The patient re-
covered uneventfully and was discharged on third postoperative
day. The patient was diagnosed with stage IIIA low grade, EESS of
the vagina and was started on the aromatase inhibitor anastrozole 1
mg daily. The patient was followed up in a combined oncology clin-
ic every month for the first 3 months; 3 monthly till 2nd year and 6
monthly till the 5th year. At every visit, a careful evaluation of symp-
toms was done, thorough clinical examination was performed and
imaging was advised accordingly. She also underwent dual-energy
X-ray absorptiometry scan every 1–2 yearly to monitor bone min-
eral density. She was on calcium and vitamin D supplementation
and was provided advice on a healthy lifestyle and importance of
regular physical exercise. At 65 months follow-up, the patient is dis-
ease-free. W e plan to continue anastrozole therapy till disease pro-
gression or development of significant toxicity in terms of osteope-
nia/osteoporosis.
normal. On bimanual examination, a hard fixed mass was felt pos-
teriorly in the rectovaginal septum. The uterus was normal in size
with restricted mobility. On rectal examination, the mucosa was
free with external compression by the mass. A repeat biopsy from
necrotic growth in the posterior fornix was suggestive of low-grade
ESS. Magnetic resonance imaging showed a T1 isointense and T2
heterogeneously enhancing hyperintense mass of 7× 6 cm in the
rectovaginal septum with an exophytic component and necrosis
with diffusion restriction (Fig. 2A).
The patient was taken up for laparotomy. Intraoperatively, the
pouch of Douglas was obliterated by a fixed mass of 7× 5 cm arising
from the posterior vaginal wall and rectovaginal septum filling the
pouch of Douglas, encasing the left ureter and invading the recto-
sigmoid. Inferiorly, the tumor was extending almost up to 4–5 cm
from the anal sphincter. A retrograde hysterectomy with excision of
posterior vaginal wall, abdominoperineal resection of rectosigmoid
colon and a permanent end colostomy was performed (Fig. 2B).
Gross histopathological examination of the specimen showed a 7.5
× 5.5× 3 cm grey-white tumor involving the rectovaginal septum,
infiltrating the serosal aspect of rectosigmoid, posterior myometri-
um up to endometrium isthmus and part of cervix. The cut end of
vaginal cuff, colonic and rectal margins were free of tumor. Bilateral
A
C D E
B
Fig. 3. (A) Sections from the uterine tumor show proliferation of endometrial stromal cells in a sheet-like pattern with formation of whorls
around arterioles suggestive of low-grade endometrial stromal sarcoma (hematoxylin and eosin staining, ×100). (B) The tumor cells are oval
to spindle-shaped and show mild nuclear atypia and fine nuclear chromatin (hematoxylin and eosin stain, ×200). The tumor cells are immu-
nopositivity for CD10 (C), ER (D), and PR (E). (C-E) Immunohistochemical staining, ×200.
76 Korean Journal of Clinical Oncology
Table 1. Review of cases reporting endometrial stromal sarcoma in vagina
Author Age
(yr)
Clinical
presentation
Previous
history of
hormonal
therapy
Size of
tumor
(cm)
Site of
tumor
Association
with
endometriosis
Stage Treatment Hormonal
therapy Immunohistochemistry Margins
Follow
up
(mo)
RFS (mo) OS
(mo) Comments
Berkowitz,
1978 [3]
57 Intermittent
vaginal bleeding,
nodule
Yes 8 Vaginal apex Yes II Exploratory
laparotomy+
radical
vaginectomy+
radiotherapy
- - - 18 18 18 H/o TAH+
BSO 15 yr
ago- no
malignancy
Ulbright,
1981 [4]
32 Vaginal nodule - 2.5 Right lateral
vagina
No I TAH+BSO+
resection of
the mass
- - - 36 36 36 -
Kondi-
Paphitis,
1998 [5]
45 Vaginal discharge,
nodules
- 2 Posterior vagina Yes II Excision of tumor - Vimentin+Desmin,
smooth muscle actin,
factor VIII, EMA and LCA –
Free 36 36 36 -
Chang,
2000 [6]
34 - - - - No - TAH+BSO+
LND+partial
vaginectomy+RT
- - - 18 18 18 -
Corpa,
2004 [7]
40 Periurethral vaginal
nodule
No 2 Periurethral No I Excision of the
nodule
- CD10, ER, PR+Desmin,
actin, S-100 protein,
and cytokeratin –
- 38 38 38 -
Masand,
2013 [1]
52 Pelvic mass - Pelvis, round
ligament,
vagina
Yes IVB Surgery+
chemoradiation
- - - 96 Yes 96 Died of
disease
51 - - Vagina No - Surgery - - - - - - Lost to
follow-up
40 Vaginal bleeding - Vagina, pelvis No III Surgery+
chemotherapy+
hormonal
therapy
- - - 9 Yes 9 Alive with
disease
44 Vaginal bleeding - Vagina, colon Yes IVA Surgery+
chemotherapy
- - - 36 Yes
(dedifferentia
ted tumor)
36 Died of
disease
49 Pelvic pain and
menorrhagia
- Ovary, uterine
serosa, vagina,
urinary bladder,
colon,
hypogastric LN
Yes IVB Surgery+
chemotherapy+
hormonal
therapy
- - - 84 Yes 84 Alive with
no evidence
of disease
(Continued to the next page)
Seema Singhal et al. • ESS from vaginal endometriosis
www.kjco.org 77
Author Age
(yr)
Clinical
presentation
Previous
history of
hormonal
therapy
Size of
tumor
(cm)
Site of
tumor
Association
with
endometriosis
Stage Treatment Hormonal
therapy Immunohistochemistry Margins
Follow
up
(mo)
RFS (mo) OS
(mo) Comments
Liu, 2013 [8] 32 Postcoital bleeding No 1 Middle and
upper right
posterior
vaginal wall
No I TAH+BSO+partial
vaginectomy+
6 cycles of
chemotherapy
(PAC)
- CD10, ER, PR and
Vimentin+desmin,
muscle actin, S-100 –
Free 18 18 18 -
Rivard, 2015
[9]
43 Asymptomatic No 5 Vaginal introitus Yes I Surgery - - - - - - -
Wang, 2015
[10]
40 Vaginal discharge,
mass
- 5 Left vagina,
bladder, rectum
No IVA Radiotherapy MPA - NA 12 Disease
progressed
during therapy
12 Died of
disease
32 Mass - 1.5 Right lower
third of vagina
No I TAH+BSO+wide
local excision
Free 21 21 21 -
Sanverdi,
2016 [11]
46 Postcoital
vaginal bleeding,
pain, constipation,
mass
No 7 Posterior fornix Yes II TAH+BSO+partial
vaginectomy
- CD10 (+), ER (+), PR (+),
and vimentin (+)
Free 22 22 22 Elevated preop
CA125 at
75 IU/mL
Abu Jamea,
2017 [12]
58 Vaginal heaviness,
mass
No 3 Left vagina No I TAH+BSO+LND Letrozole
2.5 mg
Vimentin, CD10, ER, PR,
focal CD99+h-
Caldesmon, calponin,
desmin, smooth mus-
cle actin, CD68, CD34,
Bcl-2, NSE, S100 protein,
cyclin-D1, GFAP, HMB45,
inhibin, EMA &
synaptophysin –
- 7 7 7 -
Zou, 2020
[13]
61 - - - - - I Surgery - - - 12 - 12 Alive with
disease
Tang, 2020
[14]
74 Irregular vaginal
bleeding, mass
No 6 Left vagina No - Partial
vaginectomy
- Beta-catenin, ER, PR,
vimentin+; CD10, EMA,
CD31, CD34, CD117,CD99,
SMA, desmin, h-caldesmon,
S-100, MelanA, &HMB45 –
Free 46 46 46 -
Wu, 2022
[15]
- - - - - Yes - Surgery+RT - - - - - - -
Present case 38 Pain Yes 7 Posterior fornix Yes IIIA TAH+BSO+
vaginectomy+
rectosigmoid
resection
Anastrozole
1 mg
CD10, ER, PR and focally
for cyclin D1 and
desmin+; SMA –
Free 65 65 65 -
RFS, recurrence-free survival; OS, overall survival; TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy; EMA, epithelial membrane antigen; LCA, leucocyte common antigen (CD45); LND,
lymphadenectomy; ER, estrogen receptor; PR, progesterone receptor; LN, lymph node; PAC, cisplatin, doxorubicin, and cyclophosphamide; MPA, medroxyprogesterone acetate; CA125, cancer antigen 125; RT,
radiotherapy; SMA, smooth muscle antigen.
Table 1. Continued
78 Korean Journal of Clinical Oncology